🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE

    Celgene Europe Limited

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  2. PSMA-11 kit for Ga-68 labelling

    Bial Portela & Companhia S.A.

    Intermediate and high-risk prostate cancer

    phase 3 small molecule active

    1 trial

  3. Paclitaxel

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  4. Paclitaxel

    Cellectar Biosciences

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  5. Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

    phase 3 small molecule active

    1 trial

  6. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Ningbo Cancer Hospital

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  8. Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung

    Incyte

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  9. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb Australia Pty Ltd

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  11. Paclitaxel, Cisplatin Plus 5-FU (TCF)

    The First People's Hospital of Lianyungang

    Esophageal Cancer Stage IIB

    phase 3 other active

    1 trial

  12. Palazestrant

    Olema Pharmaceuticals

    Breast Cancer

    phase 3 small molecule active

    3 trials

  13. Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant

    Olema Pharmaceuticals

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  14. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  15. Palbociclib

    Pfizer

    Metastatic Breast Cancer

    phase 3 small molecule completed

    1 trial

  16. Pamiparib capsule

    BeiGene

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  17. Pamiparib capsule

    BEONE MEDICINES AUS PTY LTD

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  18. Panitumumab

    Amgen

    Metastatic Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  19. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Ovarian Cancer

    phase 3 mab completed

    1 trial

  20. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Cervical Cancer

    phase 3 mab completed

    1 trial

  21. Pembrolizumab (K)

    Merck KGaA, Darmstadt, Germany

    Breast Cancer

    phase 3 mab active

    1 trial

  22. Pembrolizumab 25 MG/ML [Keytruda]

    United Therapeutics Europe Ltd

    Lung Cancer, Nonsmall Cell

    phase 3 small molecule active

    1 trial

  23. Pemetrexed

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  24. Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources